drugset / Trial / NCT06678048
Arsenous Acid for Refractory Triple-Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the progression-free survival (PFS) and safety of arsenous acid in combination with palliative chemotherapy for refractory triple-negative breast cancer following multiple lines of treatment.
Timeline
- Start
- 2024-10-23
- Primary completion
- 2026-04-22
- Completion
- 2026-10-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arsenous Acid | Unknown | — | — |
| Background | Epothilone D | Small molecule | — | — |
| Background | Eribulin | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Vinorelbine | Small molecule | — | — |